This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.ĭiarrhea is a leading cause of child mortality around the world, annually responsible for over 400,000 deaths among children under five years of age 1. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure – ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam.
Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually.
